Tullis-Dickerson Furthers Important Biotech/Life Science Research and Developments Via First-Quarter Investments.Business Editors and Medical Writers GREENWICH, Conn.--(BUSINESS WIRE)--April 17, 2001 Funding in Four Seed to Early Stage Companies Advances Antibodies and Anti-Infective Drug Production, Image Technologies and Genomics Tullis-Dickerson & Co., Inc., a venture capital firm with strong ties in the biomedical bi·o·med·i·cal adj. 1. Of or relating to biomedicine. 2. Of, relating to, or involving biological, medical, and physical sciences. , life sciences and healthcare technology communities and long-standing investments in underserved regional growth pockets in the Southeast, Southwest, Northeast, and Midwest, has invested in four biotech and life sciences companies during the first quarter. "Tullis-Dickerson is proud of the research and product development that each of these companies has conducted to further innovation in the field of life sciences," said Jim Tullis, Tullis-Dickerson's founder and managing principal. "We believe that each company will yield ground-breaking products and services that will advance healthcare in the very near future." Tullis-Dickerson lead a $20 million financing round for LumiCyte, Inc., a Fremont, California For the unincorporated community in Yolo County, California, see . Fremont (IPA: /ˈfriːmɒnt/) is a city in California that was incorporated on January 23, 1956, from the merger of five smaller communities: developer of patented biochip biochip Small-scale device, analogous to an integrated circuit, constructed of or used to analyze organic molecules associated with living organisms. One type of theoretical biochip is a small device constructed of large organic molecules, such as proteins, and capable of and informatics products. Joining Tullis-Dickerson in this round were OrbiMed Advisors and Redleaf Group. LumiCyte will utilize the funding to develop new genomics, proteomics, and clinical diagnostic and therapeutic opportunities. In addition, Tullis-Dickerson participated in growth financings of three companies in which it had previously provided early stage capital. In February, Tullis-Dickerson invested in the $20 million follow-on financing of Quorex Pharmaceuticals, Inc. Quorex, a Carlsbad, California Carlsbad is a coastal resort-town in northern San Diego County, California. According to the state Department of Finance, the city had a total population of 90,271 in 2003. based developer of anti-infective drugs, will utilize this venture capital financing To start an own company or to bring a new product to the market, the venture may need to attract financial funding. There are several categories of financing possibilities. If it is a small venture, then perhaps the venture can rely on family funding, loans from friends to continue its research into its quorum sensing Quorum sensing is the process by which many bacteria coordinate gene expression according to the local density of bacteria producing signaling molecules. Consequences and signaling system and to accelerate animal feasibility studies. In March, Tullis-Dickerson participated in the $15 million follow-on round of funding in San Diego, California “San Diego” redirects here. For other uses, see San Diego (disambiguation). San Diego is a coastal Southern California city located in the southwestern corner of the continental United States. As of 2006, the city has a population of 1,256,951. headquartered Epicyte Pharmaceutical, Inc. Epicyte uses Plantibody technology to turn agricultural plants into antibody factories that produce unlimited quantities of pharmaceutical-grade antibodies at prices significantly lower than animal cell, culture-based systems. Tullis-Dickerson also invested in an $18 million follow-on round of financing for Scimagix, Inc., a San Francisco San Francisco (săn frănsĭs`kō), city (1990 pop. 723,959), coextensive with San Francisco co., W Calif., on the tip of a peninsula between the Pacific Ocean and San Francisco Bay, which are connected by the strait known as the Golden based leading provider of image informatics solutions for the pharmaceutical, biotechnology and life science industries. Scimagix will use its second round of funding to expand its enterprise software systems solutions to help scientists unlock the value of scientific images to gain new insights and understanding of experimental results and chemical and biological behavior. About Tullis-Dickerson Tullis-Dickerson is a leading health care private equity group based in Greenwich, Connecticut Greenwich is a town in Fairfield County, Connecticut, United States. As of the 2000 census, the town had a total population of 61,101. It is home to many hedge funds and other financial service companies that have left Manhattan. Of the $1. . The firm invests both in the traditional venture capital centers of Boston and northern California and in underserved areas of the country. Recent news releases and other information can be found on the company's website at www.tullisdickerson.com. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion